JP2021500055A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500055A5
JP2021500055A5 JP2020523378A JP2020523378A JP2021500055A5 JP 2021500055 A5 JP2021500055 A5 JP 2021500055A5 JP 2020523378 A JP2020523378 A JP 2020523378A JP 2020523378 A JP2020523378 A JP 2020523378A JP 2021500055 A5 JP2021500055 A5 JP 2021500055A5
Authority
JP
Japan
Prior art keywords
seq
cell
lymphoma
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500055A (ja
JP7324749B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/058013 external-priority patent/WO2019082020A1/en
Publication of JP2021500055A publication Critical patent/JP2021500055A/ja
Publication of JP2021500055A5 publication Critical patent/JP2021500055A5/ja
Priority to JP2023124386A priority Critical patent/JP2023139267A/ja
Application granted granted Critical
Publication of JP7324749B2 publication Critical patent/JP7324749B2/ja
Priority to JP2024173232A priority patent/JP2024177330A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523378A 2017-10-27 2018-10-16 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用 Active JP7324749B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023124386A JP2023139267A (ja) 2017-10-27 2023-07-31 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用
JP2024173232A JP2024177330A (ja) 2017-10-27 2024-10-02 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577922P 2017-10-27 2017-10-27
US62/577,922 2017-10-27
PCT/IB2018/058013 WO2019082020A1 (en) 2017-10-27 2018-10-16 ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023124386A Division JP2023139267A (ja) 2017-10-27 2023-07-31 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用

Publications (3)

Publication Number Publication Date
JP2021500055A JP2021500055A (ja) 2021-01-07
JP2021500055A5 true JP2021500055A5 (enExample) 2021-11-25
JP7324749B2 JP7324749B2 (ja) 2023-08-10

Family

ID=64109968

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020523378A Active JP7324749B2 (ja) 2017-10-27 2018-10-16 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用
JP2023124386A Pending JP2023139267A (ja) 2017-10-27 2023-07-31 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用
JP2024173232A Pending JP2024177330A (ja) 2017-10-27 2024-10-02 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023124386A Pending JP2023139267A (ja) 2017-10-27 2023-07-31 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用
JP2024173232A Pending JP2024177330A (ja) 2017-10-27 2024-10-02 Cd123に特異的な抗体および抗体-薬物コンジュゲートならびにその使用

Country Status (18)

Country Link
US (3) US11613581B2 (enExample)
EP (1) EP3700929A1 (enExample)
JP (3) JP7324749B2 (enExample)
KR (1) KR102363746B1 (enExample)
CN (2) CN111556876B (enExample)
AU (1) AU2018357221B2 (enExample)
BR (1) BR112020008127A2 (enExample)
CA (2) CA3205442A1 (enExample)
CO (1) CO2020005347A2 (enExample)
IL (1) IL274095B2 (enExample)
MX (1) MX2020004381A (enExample)
PE (1) PE20201255A1 (enExample)
PH (1) PH12020550596A1 (enExample)
SA (1) SA520411849B1 (enExample)
SG (1) SG11202003246WA (enExample)
TW (2) TWI718427B (enExample)
WO (1) WO2019082020A1 (enExample)
ZA (1) ZA202002207B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6521959B2 (ja) * 2013-07-31 2019-05-29 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲート
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
CN111163809B (zh) 2017-09-19 2024-07-02 保罗·谢勒学院 转谷氨酰胺酶缀合方法和接头
CA3205442A1 (en) 2017-10-27 2019-05-02 Pfizer, Inc. Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
SE544015C2 (en) * 2019-06-18 2021-11-02 Tx Medic Ab Allogenic car-t cell therapy
EP4114852A1 (en) * 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN113563470B (zh) * 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
MX2023004606A (es) 2020-10-25 2023-05-08 Araris Biotech Ag Medios y metodos para producir conjugados de ligador-anticuerpo.
WO2022248835A1 (en) * 2021-05-26 2022-12-01 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
WO2023019393A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd123-targetting antibodies, chimeric antigen receptors, and uses thereof
EP4422695A1 (en) * 2021-10-25 2024-09-04 Araris Biotech AG Methods for producing antibody-linker conjugates
TW202423485A (zh) * 2022-12-08 2024-06-16 美商伊繆諾金股份有限公司 包含抗cd123抗體-藥物結合物及抗cd47抗體之治療組合
WO2025227361A1 (en) * 2024-04-30 2025-11-06 Wuxi Xdc (Shanghai) Co., Ltd. Process for preparing a composition of antibody-drug conjugates (adcs) with high d4 content
CN118416247A (zh) * 2024-04-30 2024-08-02 上海药明合联生物技术有限公司 用于制备具有高d4含量的抗体-药物缀合物(adc)组合物的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2364484A1 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
WO2010126066A1 (ja) * 2009-04-27 2010-11-04 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗IL-3Rα抗体
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
MX352738B (es) 2011-11-17 2017-12-06 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
JP6521959B2 (ja) 2013-07-31 2019-05-29 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲート
MX371147B (es) * 2014-01-27 2020-01-20 Pfizer Agentes citotoxicos bifuncionales.
KR20160145790A (ko) 2014-04-25 2016-12-20 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
HRP20200745T1 (hr) * 2014-09-05 2020-08-07 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
TN2017000275A1 (en) * 2015-01-23 2018-10-19 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Cd123抗體及其共軛物
CN107921146A (zh) * 2015-06-23 2018-04-17 拜耳医药股份有限公司 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc)
BR112017027254A2 (pt) * 2015-06-29 2019-05-14 Immunogen, Inc. anticorpos anti-cd123 e conjugados e derivados dos mesmos
US11976121B2 (en) * 2017-07-20 2024-05-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. CD123-binding chimeric antigen receptors
CA3205442A1 (en) 2017-10-27 2019-05-02 Pfizer, Inc. Antibodies and antibody-drug conjugates specific for cd123 and uses thereof

Similar Documents

Publication Publication Date Title
JP2021500055A5 (enExample)
JP6215429B2 (ja) Cd38を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ
JP6130871B2 (ja) Cd38を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ
IL274095B1 (en) Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
JP2024177330A5 (enExample)
TWI436770B (zh) 包含專一性辨識cd38之抗體及阿糖胞苷(cytarabine)之抗腫瘤組合
JP6148696B2 (ja) Cd38を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤
KR101905208B1 (ko) Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물
WO2021052402A1 (zh) 一种喜树碱衍生物及其偶联物
KR20220130160A (ko) 에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도
TW202400137A (zh) 喜樹鹼偶聯物
JP2017186337A5 (enExample)
WO2021142043A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2016505513A5 (enExample)
AU2007333485A1 (en) Methods for improving antibody production
JP2022547434A (ja) 標的化デンドリマー複合体
CN110575547A (zh) 靶向于tf的抗体-药物偶联物及其制法和用途
JP2023527257A (ja) 抗c-Met抗体薬物複合体
CN110575548A (zh) 靶向于cd73的抗体-药物偶联物及其制法和用途
WO2024145398A1 (en) Antibody drug conjugates
CN119053607A (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
JP2018528979A (ja) クインスタチン化合物
RU2830242C1 (ru) Лекарственный конъюгат производного эрибулина, способ его получения и его применение в медицине
TW202506691A (zh) Sting促效劑化合物及其結合物
WO2024193692A1 (zh) 连接子及其在配体药物偶联物中的应用